Molecular and Cellular Therapies: New challenges and opportunities
Abstract
Gene therapy is suggested to be one of the most specific and efficient modulations for gene deficient diseases and extended to other diseases like cancer and inflammation, even though there are still challenges to be faced, such as specific and selective delivery, minimal to no toxicity, efficient metabolism, simplicity, and measurable efficiency. It is important to identify and validate drug-able disease-specific targets for molecular and cellular therapies, while it is equally important to have disease biomarkers to trace and define the biological effects of molecular and cellular therapies. The importance and significance of allostery in molecular and cellular therapies and “allosteric disease”, “allosteric effect”, and “allosteric drug” should be more carefully examined and validated. Cell therapy has been attracting an increasing amount of consideration in the development of new treatments for diseases. Molecular and Cellular Therapies (MCT) is a new, open-access journal, devoted to molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies.
Downloads
References
Wright S: Systems of mating. V. General considerations. Genetics. 1921, 6 (2): 167-178.
PubMedCentralPubMedGoogle Scholar
Wright S: The distribution of gene frequencies under irreversible mutation. Proc Natl Acad Sci USA. 1938, 24 (7): 253-259. 10.1073/pnas.24.7.253.
PubMedCentralCrossRefPubMedGoogle Scholar
Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE: Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012, 150 (5): 895-908. 10.1016/j.cell.2012.08.002.
PubMedCentralCrossRefPubMedGoogle Scholar
Lima WF, Prakash TP, Murray HM, Kinberger GA, Li W, Chappell AE: Single-stranded siRNAs activate RNAi in animals. Cell. 2012, 150 (5): 883-94. 10.1016/j.cell.2012.08.014.
CrossRefPubMedGoogle Scholar
Wang XD, Ward PA: Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine. J Transl Med. 2012, 10: 220-10.1186/1479-5876-10-220.
PubMedCentralCrossRefPubMedGoogle Scholar
Peer D: A daunting task: manipulating leukocyte function with RNAi. Immunol Rev. 2013, 253: 185-197. 10.1111/imr.12044.
CrossRefPubMedGoogle Scholar
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007, 2: 751-760. 10.1038/nnano.2007.387.
CrossRefPubMedGoogle Scholar
Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M: Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008, 319: 627-630. 10.1126/science.1149859.
PubMedCentralCrossRefPubMedGoogle Scholar
Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D: RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther. 2010, 18: 370-376. 10.1038/mt.2009.271.
PubMedCentralCrossRefPubMedGoogle Scholar
Wang XD, Liotta L: Clinical bioinformatics: a new emerging science. J Clin Bioinforma. 2011, 1: 1-10.1186/2043-9113-1-1.
PubMedCentralCrossRefPubMedGoogle Scholar
Nussinov R, Tsai CJ: Allostery in disease and in drug discovery. Cell. 2013, 153 (2): 293-305. 10.1016/j.cell.2013.03.034.
CrossRefPubMedGoogle Scholar
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013, 340 (6132): 622-6. 10.1126/science.1234769.
CrossRefPubMedGoogle Scholar
Watt FM, Huck WT: Role of the extracellular matrix in regulating stem cell fate. Nat Rev Mol Cell Biol. 2013, doi:10.1038/nrm3620
Google Scholar
Xin M, Olson EN, Bassel-Duby R: Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. Nat Rev Mol Cell Biol. 2013, doi:10.1038/nrm3619
Google Scholar
Jiang J, Jing Y, Cost GJ, Chiang JC, Kolpa HJ, Cotton AM: Translating dosage compensation to trisomy 21. Nature. 2013, doi:10.1038/nature12394
Google Scholar
Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC: CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013, Epub ahead of print
Google Scholar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
Copyright on any open access article in Molecular and Cellular Therapies published bythe Institute is retained by the author(s). Authors can grant any third party the right to use
the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. Please contact the Office of Molecular and Cellular
Therapies for more information specifically regarding permissions if there are questions.
